Large global range of prices for hepatitis C medicines raises concerns about affordabilityJune 01, 2016
The prices and affordability of recently developed and highly effective direct-acting antivirals for treating hepatitis C (HCV) vary greatly among countries worldwide, according to a study published this week in PLOS Medicine. Suzanne Hill and colleagues from the World Health Organization undertook an economic analysis of prices for a 12-week course of treatment with sofosbuvir and ledipasvir/sofosbuvir in 30 countries - mostly European as well as Egypt and Mongolia, adjusting for average 2015 exchange rates and purchasing power parity (PPP). While the nominal price based on exchange rates was highest in the US (US$72,765 for a 12-week course of ledipasvir/sofosbuvir), PPP-adjusted prices in Central and Eastern European countries were highest, costing up to 1.63 times as much in Poland (PPP$118,754 for a 12 week course of ledipasvir/sofosbuvir). The researchers went on to calculate the cost of treating the entire HCV infected population in each of the countries studied. Using previous estimates of HCV burden by country, they calculated that it would range from 10.5% of the total pharmaceutical expenditure (TPE) to treat all HCV patients in the Netherlands with the new HCV medications, to 190.5% of the TPE to treat all patients in Poland.
The authors note that their analysis is limited by the accuracy of the estimates of the numbers of people infected and price information that was accessible, and that some actual prices may be lower than the publicly accessible numbers because of confidential discounts. They also note, however, that they only considered the cost of sofosbuvir and ledipasvir/sofosbuvir and did not consider extra costs of treatment such as screening and follow-up. The authors say their analysis illustrates the wide range of affordability worldwide and suggests a need for an updated pricing system: "In order for countries to increase investment and minimise the burden of hepatitis C, governments and industry stakeholders will need to jointly develop and implement fairer pricing frameworks that deliver lower and more affordable prices".
In an accompanying Perspective, Elliot Marseille and James G. Kahn discuss the pricing of these new HCV medications in relation to the high initial cost when HIV anti-retroviral therapy was introduced in the 1990s. Marseille and Kahn compare and contrast the situations, and suggest ways forward such as treating a proportion of cases initially, to spread the upfront cost of HCV treatment over several years while fighting for lower drug prices.
The authors received no specific funding for this work.
SH is a member of the PLOS Medicine Editorial Board. KTT has been an employee of Deloitte Australia within the past 5 years. Deloitte Australia has provided consulting services to pharmaceutical companies. However, KTT has not been involved in any project directly related to the content of this manuscript that can lead to conflict of interest.
Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032
World Health Organization, Geneva, Switzerland
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department, Gesundheit Ă-sterreich, Vienna, Austria
Related Hepatitis Current Events and Hepatitis News Articles
Autism care improved, diagnosis time shortened by new MU program
Wait lists for a specialist to confirm an autism diagnosis can be agonizing and last months. As the prevalence of autism and autism spectrum disorders increase, so does the demand for a health care system that is fully equipped to respond to the complex needs associated with autism.
Study reveals protein that dials immune responses up and down
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a new regulator of immune responses.
Could hepatitis C treatments help prevent virus transmission?
An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV).
Experimental drug against hepatitis C slows down Zika virus infection in mice
Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.
New study finds asthma patients rely heavily on rescue inhalers, difficult to diagnose
In a new national survey of asthma patients, Health Union, and its new online community Asthma.net, reveals that most were satisfied with the care they received; however, the most frequently used form of treatment, at 89%, is the rescue inhaler.
Alcohol accelerates liver damage in people living with hepatitis C
Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use.
Immunization rates climb when pediatricians have easy access to vaccination records
Exchange of immunization data between a centralized city immunization registry and provider electronic health records led to significant improvements in pediatric immunization coverage, a reduction in over-immunization for adolescents, and increased completeness of immunization records.
Studies demonstrate improved safety results achieved with investigational drug for hep B
Studies presented today at The International Liver Congressâ„˘ 2016 in Barcelona, Spain, demonstrate that tenofovir alafenamide (TAF) improves patient safety while maintaining efficacy in patients with chronic Hepatitis B virus (HBV) infection compared to tenofovir disoproxil fumarate (Viread, TDF).
New treatment algorithm can predict benefit of treatment in end-stage liver disease
A new algorithm designed to help physician decision-making in End-Stage Liver Disease (ESLD), was able to accurately predict death in 96% of patients with ESLD.
Study demonstrates benefits of existing treatment for hepatitis D patients
New research presented today shows that interferon alpha (IFNa) based therapies are effective in suppressing disease progression in a severe form of chronic viral hepatitis, Hepatitis delta.
More Hepatitis Current Events and Hepatitis News Articles